The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: A companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'

Annals of Oncology

Volumn 15, Issue 2, 2004, Pages 211-217

  Atalay, G ^a   Dirix, L ^b   Biganzoli, L ^a   Beex, L ^c   Nooij, M ^d   Cameron, D ^e   Lohrisch, C ^f   Cufer, T ^g   Lobelle, J P ^h   Mattiaci, M R ⁱ   Piccart, M ^a   Paridaens, Robert ^j  

^a JULES BORDET INSTITUTE   (Belgium)

^b Algemeen Ziekenhuis Sint Camillus   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g INSTITUTE OF ONCOLOGY   (Slovenia)

^h Pharmacia ^*  (Belgium)

ⁱ EORTC DATA CENTER   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Breast cancer; Exemestane; Lipid profile

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AROMATASE INHIBITOR; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BREAST CANCER; BREAST METASTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ARTERIOSCLEROSIS; BREAST NEOPLASMS; CHOLESTEROL; ENZYME INHIBITORS; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; RISK FACTORS; TAMOXIFEN;

EID: 10744233292     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh064     Document Type: Article

References (34)

1. Jemal A, Thomas A, Muray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Yue W, Santen RJ. Aromatase inhibitors: rationale for use following antiestrogen therapy. Semin Oncol 1996; 23 (Suppl 9): 21-27.
3. Bruggemeier RW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat 2002; 74: 177-185.
4. Bonneterre J, Thurliman B, Robertson JFR et al. Anastrozole versus tamoxifen as first line treatment for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000; 18: 3748-3757.
5. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
6. Nabholtz JM, Buzdar AU, Pollak M et al. Anastrozole is superior to tamoxifen as first line treatment for advanced breast cancer in postmenopausal women: results of North American Multicenter Randomized Trial. J Clin Oncol 2000; 18: 3758-3767.
7. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
8. Paridaens R, Dirix L, Beex L et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomised phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000; 1 (Suppl 1): S19-S21.
9. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocrinol Relat Cancer 1999; 6: 325-332.
10. Brown BW, Brauner C, Minotte MC. Non-cancer deaths in white adult cancer patients. J Natl Cancer Inst 1993; 85: 979-987.
11. Ginsberg HN, Goldberg IJ. Disorders of intermediary metabolism. In Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds): Harrison's Principles of Internal Medicine, 15th edition. USA: McGraw-Hill Medical Publishing Division 2001; 2245-2257.
12. LaRosa JC. Women, dyslipoproteinemia, and estrogens. Endocrinol Metab Clin North Am 1998; 27: 627-639.
13. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333.
15. Love RR, Wiebe DA, Feyzi JM et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534-1539.
16. Elisaf M, Bairaktari E, Nicolaides C et al. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 1996; 16: 2725-2728.
17. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-1467.
18. Costa LAM, Kopreski MS, Demers LM et al. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Cancer 1999; 85: 100-103.
19. Harper-Wynne CL, Sacks NPM, Shenton K et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002; 20: 1026-1035.
20. Hozumi Y, Hakamata Y, Ogura S et al. Effects of anastrozole on lipid metabolism compared with tamoxifen and toremifene in ovariectomized rats. Breast Cancer Res Treat 2002; 76 (Suppl 1); S98 (Abstr 368).
21. Dewar J, Naboltz J, Bonneterre J et al. The effect of anastrozole (Arimidex) on serum lipids - data from a randomized comparison of anastrozole (AN) versus tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 2000; 64: 51 (Abstr 164).
22. Wojtacki J, Kruszewski W, Sliwinska M et al. Effect of non steroidal aromatase inhibitors (AI) on serum lipid profile in patients with breast cancer. Preliminary report. Eur J Cancer 2000; 36: S5 (Abstr 146).
23. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001: 37: 1510-1513.
24. Nicolaides C, Elisaf M, Bairaktari E et al. The effect of aromatase inhibitor letrozole on lipid parameters in postmenopausal women with advanced breast cancer. A preliminary report. Ann Oncol 2000; 1: 12 (Abstr 380).
25. Harper-Wynne C, Ross P, Sacks N et al. A pilot prevention study of aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res Treat 2001; 69: 225 (Abstr 136).
26. Goss P, Grynpas M, Qi S et al. The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res Treat 2001; 69: 224 (Abstr 132).
27. Goss PE, Cheung AM, Lowery C et al. Comparison of the effects of exemestane, 17-hydroexemestane, and letrozole on bone and lipid metabolism in the ovariectomized rat. Breast Cancer Res Treat 2002; 76 (Suppl 1): S107 (Abstr 415).
28. Engan T, Krane J, Johannessen DG et al. Plasma changes in breast cancer patients during endocrine therapy-lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 1995; 36: 287-297.
29. Lohrisch C, Paridaens R, Dirix L et al. No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane-E) in 1st line treatment of metastatic breast cancer (MBC): A companion study to European Organization of Research and Treatment of cancer (EORTC) trial 10951. Proc Am Soc Clin Oncol 2001; 21: 43a (Abstr 167).
30. Milliken G, Jonson D. Analysis of Messy Data. Volume 1: Designed Experiments. Van Nostrand Reinhold, New York; 1993.
31. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997; 157: 961-968.
32. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998; 9: 639-645.
33. Zilembo N, Noberasco C, Bajetta E et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995; 72: 1007-1012.
34. The ATAC Trialists' Group. Arimidex, tamoxifen alone or in combination. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.